These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 17169414

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 08; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.
    Clin Cancer Res; 2009 Oct 01; 15(19):6258-66. PubMed ID: 19789313
    [Abstract] [Full Text] [Related]

  • 12. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 01; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 16. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B, Tirnitz-Parker JE, Olynyk JK.
    Gastroenterology; 2008 Sep 01; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [Abstract] [Full Text] [Related]

  • 17. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.
    Anticancer Drugs; 2006 Jul 01; 17(6):649-55. PubMed ID: 16917210
    [Abstract] [Full Text] [Related]

  • 18. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N, Yang B.
    Basic Clin Pharmacol Toxicol; 2009 Mar 01; 104(3):241-52. PubMed ID: 19159435
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells.
    Basciani S, Vona R, Matarrese P, Ascione B, Mariani S, Cauda R, Gnessi L, Malorni W, Straface E, Lucia MB.
    FEBS Lett; 2007 Dec 22; 581(30):5897-903. PubMed ID: 18061581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.